In Targeting Unmet Needs
  • New Partnerships Expand Generics Portfolio

    Pfizer is a growing force in the rapidly expanding but highly contested generics marketplace. While we have a huge generics catalog of our own, we recently entered into major licensing agreements with three India-based pharmaceutical companies, Claris Lifesciences, Aurobindo Pharma and Strides Arcolab. These agreements will bring hundreds of high-quality generic medicines to underserved populations around the world and add numerous products to Pfizer's portfolio of established brands in key markets. In addition, we launched Pfizer Injectables, a U.S.-based business offering off-patent injectables and hospital products, including Pfizer brands and generic medicines.

  • First Canine Cancer Therapy

    In 2009, Palladia, a prescription-only oral therapy, became the first FDA-approved canine cancer therapy in the U.S. It has also received marketing authorization approval in the European Union. Palladia treats mast cell tumors, the second most common type of tumor in dogs. These tumors often appear as lumps in the skin and may spread to the pet's internal organs, requiring extensive surgery, chemotherapy or radiation treatment. A tyrosine kinase inhibitor, Palladia works by blocking key receptors important for the development of blood vessels that supply tumors, as well as receptors critical for tumor survival. Palladia is now being marketed through Pfizer Animal Health.

  • Smoking Cessation Around the World

    One of Pfizer's key investments in health, the Global Health Partnerships program, has supported 32 grantees in 46 countries across five continents, funding innovative solutions to challenges in cancer and tobacco control. A partnership between the Pfizer Foundation and Pfizer's business groups across country offices, it addresses one of the world's most urgent public health problems—the ravages of smoking. Our tobacco control grantees are helping to build networks and alliances for tobacco control in nine countries, training thousands of physicians, encouraging thousands of smokers to quit, and working to protect nonsmokers from secondhand smoke. For example, the Smoke-free Hospital Program—jointly sponsored by the Pfizer Foundation, Pfizer China, the Chinese Association of Tobacco Control and the China Hospitals Association—aims to ban smoking in all public areas of participating hospitals. The program also seeks to identify and implement best practices in smoke-free regulation, as well as provide smoking cessation awareness training for health care professionals. Having reached its first-year goal of establishing smoke-free public spaces at all 40 of its participating hospitals, the program's results have supported a wider smoking ban passed by the Chinese Ministry of Health that will be adopted by all hospitals in China in 2011.

    For more information visit
  • Collaborating to Expand Research Into Neglected Diseases

    At Pfizer, we recognize our responsibility to help combat diseases that affect people in the developing world. In alliance with global health organizations, public-private partnerships and companies that share our commitment, Pfizer is conducting research programs for "neglected diseases" such as malaria, tuberculosis and river blindness.

    Working with the World Health Organization's Special Programme for Research in Tropical Diseases, we have opened access to Pfizer's library of medicinal compounds and trained scientists from developing countries. To expand screening efforts for tropical diseases such as African sleeping sickness, Pfizer is collaborating with the Drugs for Neglected Diseases Initiative while pursuing a molecular approach for this group of diseases with several U.K. universities.

    Malaria afflicts up to 250 million people annually, killing close to 1 million people a year, mostly children in Africa. We are providing the Medicines for Malaria Venture (MMV) access to Pfizer's library of chemical entities to screen approximately 200,000 compounds that have the potential to be developed into new treatments against P. falciparum, the parasite that causes acute malaria, including multidrug-resistant strains. In consultation with MMV and the London School of Hygiene & Tropical Medicine we are in Phase III development of the combination of azithromycin and chloroquine as a potential treatment of malaria. In addition, Pfizer and the Italian firm Sigma-Tau entered into a license-and-supply agreement to market Eurartesim, a novel, fixed-dose, once-daily, artemisinin-based combination therapy, in Africa. This product, which is currently under review by the European Medicines Agency, aims to treat uncomplicated P. falciparum malaria in adults and children, while reducing the potential for re-infection. If these products are approved by regulatory authorities, the partnerships will expand access for underserved populations while allowing Pfizer to realize a commercial return, an approach we believe will prove sustainable for our business and for society.

    For more information visit
  • Partnering With the Clinton Foundation to Fight HIV/AIDS

    Pfizer has entered into a partnership with the Clinton Foundation HIV/AIDS Initiative that will reduce the cost and expand the availability of rifabutin, an antibiotic used to treat tuberculosis in HIV/AIDS patients taking second-line antiretroviral therapy. Tuberculosis is a leading killer of those who succumb to HIV/AIDS. For five years, rifabutin prices will be capped in emerging markets at $1 per 150 mg dose, or $90 for the six-month full course of treatment—a reduction of 60 percent. This will foster greater access to rifabutin, which was recently added to the WHO Model List of Essential Medicines.

  • Toviaz Launches in U.S.

    Overactive bladder (OAB) affects more than 33 million Americans—men and women—and can affect anyone at any time. Yet awareness of OAB's symptoms and treatments has been quite low, primarily because of reluctance by patients to talk to doctors about their condition. With the launch of Toviaz, Pfizer's latest prescription treatment for OAB, the company not only introduced the brand to patients and physicians, but also developed a support plan, called YourWay, to help OAB patients manage the condition. The YourWay support plan is available at no charge. Information can be delivered by e-mail, telephone or Web site.

  • Consumer Products Maintain Momentum

    As people worldwide become increasingly aware of issues surrounding health and wellness, they're taking more proactive roles to maintain their personal well-being and treat minor illnesses through self-care solutions. Pfizer's solutions range from Advil pain relievers to ThermaCare heatwraps.

    Pfizer Consumer Healthcare—already one of the world's leaders in the development, manufacturing and marketing of nonprescription medicines, vitamins and nutritional products—is continually bringing to market new products and line extensions that meet evolving needs for self-care solutions.

    For example, early in 2009, we introduced the Centrum Ultra line of products in the U.S. Centrum Ultra is a scientifically advanced line of gender- and age-specific multivitamins specially formulated to help meet the nutritional needs of men and women. The success of Centrum Ultra in its first year represents Pfizer Consumer Healthcare's largest new product launch in the U.S. since Advil.

    Also, in the fourth quarter of 2009 we introduced advanced new formulas of Centrum and Centrum Silver/Select 50+ in 14 European markets. This patent-pending formula upgrade is a major milestone that represents a significant opportunity to grow the Centrum business throughout Europe. Advanced Centrum and Centrum Silver/Select 50+ contain specially adjusted levels of key vitamins and minerals to help fill nutritional gaps and deliver multiple health benefits such as energy, immunity, healthy appearance, eye health, bone health and environmental stress protection.